NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 29 September 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, will present new data from their on-going clinical research at Read More
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 20 June 2019 – Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using Read More
BluePrint® Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes
PRESS RELEASE New data presented at ASCO underscores importance of genomic profiling for African-American women with breast cancer whose unique tumor biology can sometimes lead to poorer prognoses IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS Read More
Agendia Appoints Two Industry Veterans to Board of Directors
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to Read More
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the Read More
New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ basal-type demonstrated significant response to chemotherapy underscoring critical role of advanced diagnostic tools Results published in Nature Publishing Group’s npj Breast Cancer IRVINE, CALIF., U.S., and Read More
Agendia Announces Creation of New Center of Innovation and R&D Excellence
PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 17 April 2019 – Agendia, Inc., a world leader in precision oncology, announced today that it has created Read More
